Macquarie dropped the price target of Mediclinic International Plc (LON:MDC) to 760.00GBX stating a potential upside of 0.05%.
On 4/4/2017, Macquarie released a statement for Mediclinic International Plc (LON:MDC) bumped down the target price from 860.00GBX to 770.00GBX that suggested an upside of 0.11%.
See Chart Below
Mediclinic International Plc has a one year low of 666.50GBX and a one year high of 1,125.00GBX with a price-earnings ratio of 27.67 The company’s market cap is currently 0 GBX.
In addition to Macquarie reporting its Stock price target, a total of 1 broker has issued a report on the company. The average stock price target is 2.50GBX with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Mediclinic International Plc (LON:MDC)
Mediclinic International plc is an international private healthcare provider. The Company's segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company. It has approximately 70 hospitals and over 40 clinics across its operating platforms. Mediclinic Southern Africa operates approximately 50 hospitals and over two day-clinics across South Africa, and over three hospitals in Namibia with approximately 8,000 in-patient beds. It has interest in Hirslanden AG, which operates over 20 private acute care facilities and approximately four clinics in Switzerland with over 1,600 in-patient beds. Mediclinic Middle East operates over five hospitals and approximately 40 clinics with over 600 in-patient beds in the United Arab Emirates.
The post Mediclinic International Plc (LON:MDC) stock price target bumped down to 760.00GBX, released a research note earlier today by Macquarie appeared first on Octafinance.